FDA warning letter cites Genzyme's Waterford, Ireland site for data integrity failures and improperly canceled deviations following a January inspection.
An FDA warning letter sent late last month to Genzyme’s Ireland-based manufacturing site, now owned by Sanofi, raises significant quality- and data-related issues.
On data …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
After a site visit by FDA inspectors yielded a Form 483 for Genzyme Ireland in early 2026, the Sanofi subsidiary is facing…
The FDA has hit QOL Medical with an untitled letter over emails about Sucraid, accusing the company of creating a misleading…
Novo Nordisk’s troubled factory in Indiana that it got from Catalent continues to face contamination issues, with a re-inspection…
A June inspection now has the FDA hitting Dr. | The agency spotted seven observations at Dr. Reddy's Bachupally, Hyderabad,…
As Amgen prepares to defend Tavneos’ market approval in the U.S., the company has received a bad omen overseas, with regulators…
Novo Nordisk’s troubled factory in Indiana that it got from Catalent continues to face contamination issues, with a re-inspection…
